The Cystinosis Research Network welcomes Clinton Moore to the Board of Directors as VP of Family Support.
Dr. Galina Nesterova completes CRN NIH Clinical Fellowship, takes position in Vancouver, B.C.
The Cystinosis Research Network is indebted to Dr. Nesterova for dedicating a significant portion of her career to the treatment of hundreds of individuals with cystinosis. She has become an expert in the disorder and continues to be one of our community's greatest advocates.
We are pleased to announce that she will be joining CRN's Medical Advisory Board and will thus continue her outstanding service to the cystinosis community.
NOVATO, Calif., March 21, 2016 -- Raptor Pharmaceutical Corp. (Nasdaq: RPTP) today announced that Health Canada has accepted for review its New Drug Submission (NDS) for PROCYSBI® (cysteamine bitartrate) delayed-release capsules for the treatment of nephropathic cystinosis (NC), with Priority Review status. Priority Review provides for a shortened review process of 180 days compared to a standard 300 days. Raptor estimates, based on information provided by physicians, that there are approximately 100 individuals affected by nephropathic cystinosis in Canada. PROCYSBI, a cystine depleting agent, is approved in the U.S. for the treatment of NC in adults and children ages two years and older and in all patients with NC in Europe.
“I am pleased that PROCYSBI has been accepted for review in Canada and that the review process will be expedited,” said Krishna Polu, M.D., Chief Medical Officer of Raptor Pharmaceutical Corp. “There are currently no approved cystine depleting agents in Canada and the Priority Review status by Health Canada acknowledges the urgent unmet need Canadian patients with Cystinosis have for accessing PROCYSBI.”